Stable gastric pentadecapeptide BPC 157 in trials for inflammatory bowel disease (PL-10, PLD-116, PL 14736, Pliva, Croatia). Full and distended stomach, and vascular response.
Level 5 - mechanism / opinion, no new human data
Narrative review describing preclinical animal experiments and mechanism-based reasoning with no human clinical trial data presented
PubMed 17186181 · doi:10.1007/s10787-006-1531-7
What was done
This narrative review summarizes experimental findings on the synthetic gastric pentadecapeptide BPC 157 (GEPPPGKPADDAGLV). It describes preclinical rat experiments examining vascular and mucosal responses following absolute alcohol instillation into fully distended stomachs, comparing BPC 157 to standard agents (atropine, ranitidine, omeprazole). It also reviews reported mechanistic pathways, including nitric oxide modulation, endothelin and angiogenesis regulation, central dopamine/serotonin interaction, and sphincter pressure restoration in rats after 12–20 months of untreated esophagitis.
What was found
The abstract reports no numerical values, sample sizes, or statistical metrics. Directionally, alcohol instillation into distended rat stomachs caused left gastric artery blood vessels at the serosal site to disappear within 3 minutes alongside esophageal, gastric, and duodenal lesion development. Direct intragastric instillation of BPC 157 maintained vessel presentation and inhibited lesion formation, outperforming standard agents which showed only slight vessel improvement and partial lesion inhibition. BPC 157 was also noted to immediately restore disturbed lower esophageal and pyloric sphincter pressures in chronic rat esophagitis models.
Why it matters
The review synthesizes early preclinical evidence proposing BPC 157 as a broad-spectrum cytoprotective and microvascular-stabilizing peptide for gastrointestinal injury.
Limits
The described findings come from animal (rodent) models, and no human clinical data or methodology are detailed in the abstract. The narrative format does not report sample sizes, specific dosages, or quantitative comparisons, and potential human translation remains unverified in this text.
Cited by
- context A Croatian clinical trial evaluated rectal enemas of BPC-157 at doses up to 80 milligrams in patients with ulcerative colitis, finding no adverse events in phase 1 and absence of systemic drug levels in the blood.